President Donald Trump wants drugmakers to work with his federal health department to reach an agreement on a most favored nation price for their medicines.

This study identifies 53BP1 as an interaction partner of GMCL1 (a likely CUL3 substrate receptor). The study seeks to link this finding to regulation of the mitotic surveillance pathway and paclitaxel ...

Industrial fermentation using bacteria, yeast and other microbes to produce specific products has the potential to reduce ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

The applications did not adequately show possession of an operable CRISPR-Cas9 system in eukaryotic cells, even though they described the core components of the technology. As a result ...

The only gene-editing therapy currently on the market is a CRISPR–Cas9-based treatment for two blood disorders, sickle-cell disease and β-thalassaemia. This costs more than US$2 million per ...

At stake in the ongoing patent dispute over the gene-editing tool are rights to the most important new biotechnology of the age and credit for inventing it. The CRISPR patents are back in play.

This is the rate based on his employer’s medical insurance. Under the Build Back Better proposal, copay prices for insulin products could not exceed $35 for Medicare Part D and private group or ...

In 1982, Novo marketed Human Monocomponent Insulin, and in 1987, the first human insulin products were made using genetically engineered yeast cells. Novo launched the NovoPen - the first insulin pen ...

Sanjay Basu, Waymark, San Francisco, California. Kasia J. Lipska, Yale University. Insulin is considered an essential medicine for people with diabetes, but its price has doubled during the past ...

Biotech authority The Petersburg plant, which is expected to bring 186 jobs, will begin producing finished insulin products in the third quarter of 2023 and should begin selling in 2024.

A Sanofi subsidiary has claimed FDA approval for the first biosimilar of Novo Nordisk's Novolog, an older formulation of the Danish pharma's blockbuster insulin analogue product insulin aspart.